Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency

Key Points Question What is the safety, tolerability, pharmacodynamic, and pharmacokinetic profile of the histone deacetylase inhibitor FRM-0334 in participants with progranulin gene (GRN) haploinsufficiency? Findings In this randomized placebo-controlled clinical trial including 27 participants with GRN haploinsufficiency, FRM-0334 was safe and well tolerated; however, it failed to increase plasma progranulin and cerebrospinal fluid progranulin and failed to demonstrate dose-dependent oral bioavailability. Meaning The studied formulation of FRM-0334 should not be investigated in future clinical trials enrolling participants with GRN haploinsufficiency; this study did not fully address the potential of histone deacetylase inhibition to alter GRN expression.

[1]  David T. Jones,et al.  Use of the CDR® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium , 2019, Alzheimer's & Dementia.

[2]  A. Fagan,et al.  Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory , 2018, Annals of clinical and translational neurology.

[3]  Jesse A. Brown,et al.  An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations , 2017, Alzheimer's & dementia.

[4]  Z. Modrušan,et al.  Progranulin deficiency causes impairment of autophagy and TDP-43 accumulation , 2017, The Journal of experimental medicine.

[5]  Param Priya Singh,et al.  Progranulin, lysosomal regulation and neurodegenerative disease , 2017, Nature Reviews Neuroscience.

[6]  Y. Pijnenburg,et al.  Progranulin Levels in Plasma and Cerebrospinal Fluid in Granulin Mutation Carriers , 2016, Dementia and Geriatric Cognitive Disorders Extra.

[7]  S. Ourselin,et al.  Neurofilament light chain: a biomarker for genetic frontotemporal dementia , 2016, Annals of clinical and translational neurology.

[8]  Vrishabhsagar Ruikar,et al.  Interactive Voice/Web Response System in clinical research , 2016, Perspectives in clinical research.

[9]  Aditya Kumar Bubna,et al.  Vorinostat—An Overview , 2015, Indian journal of dermatology.

[10]  A. L. Munain,et al.  Increasing progranulin levels and blockade of the ERK1/2 pathway: Upstream and downstream strategies for the treatment of progranulin deficient frontotemporal dementia , 2015, European Neuropsychopharmacology.

[11]  L. Grinberg,et al.  Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration , 2014, Annals of neurology.

[12]  V. Sossi,et al.  Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers , 2013, Neurology.

[13]  Min Jae Lee,et al.  Tau degradation: The ubiquitin–proteasome system versus the autophagy-lysosome system , 2013, Progress in Neurobiology.

[14]  Pierre J Magistretti,et al.  Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. , 2011, Cell metabolism.

[15]  Barbara Stanley,et al.  The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. , 2011, The American journal of psychiatry.

[16]  Robert V Farese,et al.  Suberoylanilide Hydroxamic Acid (Vorinostat) Up-regulates Progranulin Transcription , 2011, The Journal of Biological Chemistry.

[17]  N. Bresolin,et al.  Cerebrospinal fluid biomarkers in Progranulin mutations carriers. , 2011, Journal of Alzheimer's disease : JAD.

[18]  M. Hornberger,et al.  Clinical Staging and Disease Progression in Frontotemporal Dementia Supplemental Data at Www.neurology.org , 2022 .

[19]  R. Petersen,et al.  Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members , 2009, Brain : a journal of neurology.

[20]  Nathaniel Mercaldo,et al.  Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. , 2008, Brain : a journal of neurology.

[21]  C. Haass,et al.  Missense Mutations in the Progranulin Gene Linked to Frontotemporal Lobar Degeneration with Ubiquitin-immunoreactive Inclusions Reduce Progranulin Production and Secretion* , 2008, Journal of Biological Chemistry.

[22]  S. Targum,et al.  The clinical global impressions scale: applying a research tool in clinical practice. , 2007, Psychiatry (Edgmont (Pa. : Township)).

[23]  P. Pietrini,et al.  Clinicopathologic features of frontotemporal dementia with Progranulin sequence variation , 2007, Neurology.

[24]  S. Melquist,et al.  Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. , 2006, Human molecular genetics.

[25]  S. Melquist,et al.  Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17 , 2006, Nature.

[26]  A. Petzold.  Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss , 2005, Journal of the Neurological Sciences.

[27]  A. Bateman,et al.  The complementary deoxyribonucleic acid sequence, tissue distribution, and cellular localization of the rat granulin precursor. , 1993, Endocrinology.